For Non-US Residents

Learn more about Tasmar

Are you or a loved one new to TASMAR? Learn more about how this medicine can help you.

Tasmar

For those on TASMAR, the frequency of liver monitoring has recently decreased. Read about the updated Food and Drug Administration (FDA) approved labeling change, and learn what that may mean for you or your loved one.

The use of TASMAR® (tolcapone) as an adjunct therapy to levodopa and carbidopa can help to bring Parkinson’s disease symptoms under control. Adjunct therapies are medicines used in combination with other medicines. TASMAR is most effective when a patient has begun experiencing wearing off, when the effectiveness of their existing Parkinson’s medicines decreases.

TASMAR SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT HAS PROVIDED WRITTEN INFORMED CONSENT (SEE PATIENT ACKNOWLEDGEMENT FORM).

WARNING: Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND ADMINISTRATION sections).

TASMAR therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).

Laboratory Tests: Although a program of frequent laboratory monitoring for evidence of hepatocellular injury is deemed essential, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.

Please see accompanying complete prescribing information including BOXED warning.